바이젠셀

308080KOSDAQ자연과학 및 공학 연구개발업

45.5 / 100

Reference Date: 2026-07-24

Financial Score13.0 / 40

News Sentiment19.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Plunged 18.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Bizen Cell is a biotech venture company established in 2013, specializing in the development and manufacturing of immunotherapy drugs. Leveraging its HLA research expertise and utilizing umbilical cord blood-derived immune therapies, the company is advancing as a cell therapy specialist through pipelines such as ViTier and ViMedier, while expanding into global new drug development and advanced regenerative medicine.

Number of Employees

43people

Average Salary

86.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

—Industry Average 2.523.5Point

ROE

-32.09Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

20.24Industry Average 7.310.0Point

2.8x industry avg (risky)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼91.9% (1-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -25.3% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 6Neutral 0Negative 1Average Sentiment Score 77.9

Positive
“4년간 사망 0명, 왜 가능했나”…바이젠셀 VT-EBV-N 임상책임자...
바이젠셀의 VT-EBV-N 임상 성공으로 인해 치료 효과 지속성에 대한 긍정적 전망이 제기되었다.
Negative
[생생확대경] 4월 승인받고도 10월 투약…환자 골든타임 삼키는 ‘3중...
바이젠셀의 승인 지연으로 환자들의 치료 골든타임이 위협받고 있다.
Positive
기평석 바이젠셀 대표 "유전자 편집해 더 강한 세포치료제…뇌종양 환.....
바이젠셀의 기평석 대표가 동물임상에서 NK세포 기반 항암제의 효과를 확인하며, 고형암 치료에 특화된 혁신적인 세포치료제 개발을 강조했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 5,400Won52-week high 15,80052-week low 3,090

1-month return0.0Point

1m -18.31% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0